John Lauriello, MD
Department of Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia, Pennsylvania
Original Research
Long-Term Safety of Aripiprazole Lauroxil
August 18, 2020
Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
Academic Highlights
Schizophrenia Remission Roller Coaster
June 30, 2020
In this journal CME activity, find experts' recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
Educational Activity
Improving Adherence to Schizophrenia Treatment
March 26, 2019
Relapse of schizophrenia often occurs due to treatment nonadherence. Long-acting injectable (LAI) antipsychotics can improve adherence but are underused. Watch this Webcast to hear interviews with patients and learn...
Educational Activity
Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
February 21, 2018
Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and outcomes for patients with serious mental illness but are underused. Watch this Webcast to learn how to identify...
